Cortoss enters kyphoplasty trial in US:
This article was originally published in Clinica
Orthovita is to begin a second pilot clinical study to evaluate its Cortoss synthetic cortical bone void filler in the treatment of vertebral compression fractures (VCF) using a treatment technique called kyphoplasty. During kyphoplasty, an inflatable bone tamp is used to reduce the fracture and create a void in which the CORTOSS biomaterial can be injected. In January 2003, Orthovita began its first US pilot clinical study of CORTOSS for treating VCF using the vertebroplasty technique, whereby the biomaterial is injected without using the inflatable device. In the same month, the Malvern, Pennsylvania firm gained European approval to market the product for vertebral augmentation, including the repair of VCF.
You may also be interested in...
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.